News
ANGO
--
0.00%
--
Insider Trends: AngioDynamics Insider Exercises Option/Derivative Security to Acquire Stock Sells Portion to Pay Tax, Buy Trend Intact
MT Newswires · 17h ago
PAVmed Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare Technology CEO by Healthcare Technology Report
NEW YORK, April 15, Apr 15, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company"...
GlobeNewswire · 1d ago
AngioDynamics (ANGO) Receives a Buy from Raymond James
In a report released today, Jayson Bedford from Raymond James maintained a Buy rating on AngioDynamics (ANGO). The company's shares closed last Monday at
SmarterAnalyst · 4d ago
AngioDynamics Submits 510(K) Application For AlphaVac System
Minimally invasive medical devices provider AngioDynamic Inc has submitted a 510(K) application for its AlphaVac System to the U.S. Food and Drug Administration (FDA). The Alphavac System is an off-circuit, multi-purpose mechanical aspiration thrombectomy ...
SmarterAnalyst · 4d ago
DJ AngioDynamics Seeks FDA Clearance for Mechanical Thrombectomy System
Dow Jones · 5d ago
BRIEF-Angiodynamics Submits 510(K) Application To FDA For Alphavac Mechanical Thrombectomy System
reuters.com · 5d ago
AngioDynamics files AlphaVac System application in U.S.
AngioDynamics (ANGO) has submitted a 510(k) application to the FDA for the AlphaVac System, an off-circuit, multi-purpose mechanical aspiration thrombectomy device for the treatment of undesirable intravascular material in the
Seekingalpha · 5d ago
AngioDynamics Submits 510(k) Application to FDA for AlphaVac Mechanical Thrombectomy System
AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology today announced that on April 9, 2021, it submitted a
Benzinga · 5d ago
Raymond James Sticks to Its Buy Rating for AngioDynamics (ANGO)
Raymond James analyst Jayson Bedford maintained a Buy rating on AngioDynamics (ANGO) yesterday. The company's shares closed last Wednesday at $23.60,
SmarterAnalyst · 04/08 11:15
The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 6)
Benzinga · 04/07 11:57
Clot Management Devices Market Size & Share | Industry Trends & COVID-19 Impact Analysis
SUPER MARKET RESEARCH · 04/06 02:53
Guidewires Market Size & Share 2020 | Industry Trends by Product, by Material, by Application, by End User
SUPER MARKET RESEARCH · 04/05 23:34
AngioDynamics to Present at the Needham Virtual Healthcare Conference
AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Tro...
BusinessWire · 04/05 20:01
The Daily Biotech Pulse: Pfizer-BioNTech Preps For BLA Filing, Sonoma Surges, BioXcel Readout, Ortho Clinical Lands Contract
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 31)
Benzinga · 04/01 11:46
AngioDynamics (ANGO) Soars 7.9%: Is Further Upside Left in the Stock?
Zacks.com · 03/31 21:32
AngioDynamics (ANGO) Q3 Earnings and Revenues Top Estimates
AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q3.
Zacks · 03/31 17:59
10-Q: ANGIODYNAMICS INC
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. The following information should...
Edgar Online - (EDG = 10Q, 10K) · 03/31 16:11
AngioDynamics Gains 8% After A Blowout 3Q
Shares of AngioDynamics popped 7.9% on Tuesday after the medical devices company reported impressive third-quarter results. The company also provided FY21 guidance that fared better than analysts’ estimates. AngioDynamics’ (ANGO) 3Q revenues grew 2% year-o...
SmarterAnalyst · 03/31 15:35
DJ AngioDynamics Price Target Raised to $24.00/Share From $18.00 by Canaccord Genuity
Dow Jones · 03/31 13:40
DJ AngioDynamics Is Maintained at Hold by Canaccord Genuity
Dow Jones · 03/31 13:40
Webull provides a variety of real-time ANGO stock news. You can receive the latest news about AngioDynamics through multiple platforms. This information may help you make smarter investment decisions.
About ANGO
AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Vascular Interventions & Therapies, Vascular Access and Oncology. The Company's Vascular Interventions & Therapies products include Venous, Thrombus Management, as well as other core products. The Company's BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines. Through its subsidiary, Eximo Medical, Ltd., the Company operates 355 nanometers (nm) wavelength laser-technology platform.